Export

You can select particular sections to be included in the output file.

Model List of Essential Medicines

clear Found 215 recommendations for 71 medicines and 7 therapeutic equivalents
Removed recommendations and rejected applications are shown. Hide them.
8. Immunomodulators and antineoplastics
  1. Abiraterone General information
    Section
    Hormones and antihormones
    • Oral > Solid: 250 mg; 500 mg
  2. Adalimumab General information
    Section
    Immunomodulators for non-malignant disease
    • Parenteral > General injections > SC: 40 mg per 0.8 mL; 40 mg per 0.4 mL
  3. Afatinib General information
    Section
    Targeted therapies
  4. All-trans retinoic acid General information
    Section
    Targeted therapies
    • Oral > Solid: 10 mg capsule
  5. Allopurinol General information
    Section
    Supportive medicines
    • Oral > Solid: 100 mg tablet; 300 mg tablet
  6. Anastrozole General information
    Section
    Hormones and antihormones
    • Oral > Solid: 1 mg tablet
  7. Arsenic trioxide General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 1 mg per mL concentrate for solution for infusion
  8. Asparaginase General information
    Section
    Cytotoxic medicines
    • Powder for injection: 10 000 IU in vial.
    • Parenteral > General injections > unspecified: 10000 IU in vial powder for injection
  9. Atezolizumab General information
    Section
    Immunomodulators
    • Parenteral > General injections > IV: 1.2 g per 20 mL concentrate solution for infusion
  10. Azathioprine General information
    Section
    Immunomodulators for non-malignant disease
    • Parenteral > General injections > IV: 100 mg in vial powder for injection (as sodium salt)
    • Oral > Solid: 50 mg
  11. Bendamustine General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > unspecified: 45 mg per 0.5 mL; 180 mg per 2 mL
  12. Bicalutamide General information
    Section
    Hormones and antihormones
    • Oral > Solid: 50 mg
  13. Bortezomib General information
    Section
    Targeted therapies
    • Parenteral > General injections > unspecified: 3.5 mg in vial powder for injection
  14. Certolizumab pegol General information
    Section
    Immunomodulators for non-malignant disease
    Indications
    Therapeutic equivalent to adalimumab for Axial spondyloarthritis Therapeutic equivalent to adalimumab for Juvenile idiopathic arthritis Therapeutic equivalent to adalimumab for Crohn disease site Therapeutic equivalent to adalimumab for Rheumatoid arthritis
  15. Ciclosporin General information
    Section
    Immunomodulators for non-malignant disease
    • Parenteral > General injections > IV: 50 mg per mL in 1 mL ampoule concentrate for injection
    • Oral > Solid: 25 mg
  16. Crizotinib General information
    Section
    Targeted therapies
    • Oral > Solid: 200 mg; 250 mg
  17. Cyclophosphamide General information
  18. Dacarbazine General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 100 mg in vial powder for injection
    Indications
  19. Dasatinib General information
    Section
    Targeted therapies
    • Oral > Solid: 20 mg tablet; 50 mg tablet; 70 mg tablet; 80 mg tablet; 100 mg tablet; 140 mg tablet
  20. Daunorubicin General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 50 mg in vial (hydrochloride) powder for injection
  21. Dexamethasone General information
    Section
    Hormones and antihormones
    • Oral > Solid: 4 mg
    • Parenteral > General injections > unspecified: 4 mg per mL in 1 mL ampoule (as disodium phosophate salt)
    • Oral > Liquid: 2 mg per 5 mL
    • Oral > Solid: 2 mg; 4 mg
  22. Enzalutamide General information
    Section
    Hormones and antihormones
    • Oral > Solid: 40 mg
  23. Erlotinib General information
    Section
    Targeted therapies
    • Oral > Solid: 100 mg; 150 mg
  24. Etanercept General information
    Section
    Immunomodulators for non-malignant disease
    Indications
    Therapeutic equivalent to adalimumab for Axial spondyloarthritis Therapeutic equivalent to adalimumab for Juvenile idiopathic arthritis Therapeutic equivalent to adalimumab for Crohn disease site Therapeutic equivalent to adalimumab for Rheumatoid arthritis
  25. Filgrastim General information
    Section
    Immunomodulators
    • Parenteral > General injections > SC: 120 µg per 0.2 mL in prefilled syringe; 300 µg per 0.5 mL in prefilled syringe; 480 µg per 0.8 mL in prefilled syringe; 300 µg per mL in 1 mL vial; 480 µg per 1.6 mL in 1.6 mL vial
  26. Fingolimod General information
    Section
    Immunomodulators for non-malignant disease
    • Oral > Solid: 0.25 mg; 0.5 mg
  27. Fludarabine General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 50 mg in vial (fludarabine phosphate) powder for injection
    • Oral > Solid: 10 mg tablet (fludarabine phosphate)
  28. Gefitinib General information
    Section
    Targeted therapies
  29. Gemcitabine General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 200 mg in vial powder for injection; 1 g in vial powder for injection
  30. Glatiramer acetate General information
    Section
    Immunomodulators for non-malignant disease
    • Parenteral > General injections > SC: 20 mg per mL; 40 mg per mL
  31. Golimumab General information
    Section
    Immunomodulators for non-malignant disease
    Indications
    Therapeutic equivalent to adalimumab for Axial spondyloarthritis Therapeutic equivalent to adalimumab for Juvenile idiopathic arthritis Therapeutic equivalent to adalimumab for Crohn disease site Therapeutic equivalent to adalimumab for Rheumatoid arthritis
  32. Hydrocortisone General information
    Section
    Hormones and antihormones
    • Parenteral > General injections > unspecified: 100 mg in vial (as sodium succinate)
  33. Hydroxycarbamide General information
    Section
    Cytotoxic medicines
    • Oral > Solid: 200 mg; 250 mg; 300 mg; 400 mg; 500 mg; 1 g
  34. Ifosfamide General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 500 mg in vial powder for injection; 1 g in vial powder for injection; 2 g in vial powder for injection
    • Parenteral > General injections > IV: 1 g in vial powder for injection; 2 g in vial powder for injection
  35. Imatinib General information
    Section
    Targeted therapies
    • Oral > Solid: 100 mg tablet; 400 mg tablet
  36. Infliximab General information
    Section
    Immunomodulators for non-malignant disease
    Indications
    Therapeutic equivalent to adalimumab for Axial spondyloarthritis Therapeutic equivalent to adalimumab for Juvenile idiopathic arthritis Therapeutic equivalent to adalimumab for Crohn disease site Therapeutic equivalent to adalimumab for Rheumatoid arthritis
  37. Irinotecan General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 40 mg per 2 mL in 2 mL vial; 100 mg per 5 mL in 5 mL vial; 500 mg per 25 mL in 25 mL vial
  38. Lenalidomide General information
    Section
    Immunomodulators
    • Oral > Solid: 25 mg
  39. Leuprorelin General information
    Section
    Hormones and antihormones
    • Parenteral > General injections > IM: 7.5 mg in prefilled syringe; 22.5 mg in prefilled syringe
  40. Melphalan General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 50 mg in vial powder for injection
    • Oral > Solid: 2 mg
  41. Methylprednisolone General information
    Section
    Hormones and antihormones
    • Parenteral > General injections > IV: 40 mg per mL in 1 mL single-dose vial (as sodium succinate); 40 mg per mL in 5 mL multi-dose vial (as sodium succinate); 80 mg per mL in 1 mL single-dose vial (as sodium succinate)
  42. Nilotinib General information
    Section
    Targeted therapies
    • Oral > Solid: 150 mg capsule; 200 mg capsule
  43. Nivolumab General information
    Section
    Immunomodulators
    • Parenteral > General injections > IV: 10 mg per mL concentrate solution for infusion
  44. Ocrelizumab General information
    Section
    Immunomodulators for non-malignant disease
    • Parenteral > General injections > IV: 30 mg per mL in 10 mL vial
  45. Oxaliplatin General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 50 mg in vial powder for injection; 100 mg in vial powder for injection; 50 mg per 10 mL in 10 mL vial; 100 mg per 20 mL in 20 mL vial; 200 mg per 40 mL in 40 mL vial
  46. Pegaspargase General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 3750 units per 5 mL in vial
  47. Pembrolizumab General information
    Section
    Immunomodulators
    • Parenteral > General injections > IV: 50 mg powder for injection
  48. Pertuzumab General information
    Section
    Targeted therapies
    • Parenteral > General injections > IV: 240 mg per 14 mL in 14 mL vial concentrated solution
  49. Procarbazine General information
    Section
    Cytotoxic medicines
    • Oral > Solid: 50 mg (as hydrochloride)
  50. Realgar-indigo naturalis formulation General information
    Section
    Cytotoxic medicines
    • Oral > Solid: 270 mg (containing tetra-arsenic tetra-sulfide 30 mg)
  51. Rituximab General information
    Section
    Targeted therapies
    • Parenteral > General injections > IV: 100 mg per 10 mL in 10 mL vial; 500 mg per 50 mL in 50 mL vial
  52. Tamoxifen General information
    Section
    Hormones and antihormones
    • Oral > Solid: 10 mg (as citrate); 20 mg (as citrate)
  53. Thalidomide General information
    Section
    Immunomodulators
    • Oral > Solid: 50 mg
  54. Tioguanine General information
    Section
    Cytotoxic medicines
    • Oral > Solid: 40 mg
  55. Trastuzumab General information
    Section
    Targeted therapies
    • Parenteral > General injections > IV: 60 mg in vial powder for injection; 150 mg in vial powder for injection; 440 mg in vial powder for injection
  56. Trastuzumab emtansine General information
    Section
    Targeted therapies
    • Parenteral > General injections > IV: 100 mg in vial powder for injection; 160 mg in vial powder for injection
  57. Vinorelbine General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 10 mg per mL in 1 mL vial; 50 mg per 5 mL in 5 mL vial
  58. Zoledronic acid General information
    Section
    Supportive medicines
    • Parenteral > General injections > IV: 4 mg per 5 mL in 5 mL vial; 4 mg per 100 mL in 100 mL bottle